corporate culture

The corporate culture of the Group takes "benevolence, righteousness, courtesy, wisdom and trust" as the core, integrates modern management concepts, and then permeates all positions through the spirit of enterprise, practicing "growing in revision and revising in growth", which greatly improves the cohesion of the enterprise, enhances the sense of historical mission and social responsibility of employees, and realizes the overall improvement of employees' quality.

In 2003, Revision Pharmaceutical Group "China Growth Enterprise Revision Organization" won the China Corporate Culture Innovation Award. In 2004, the revised organization "New Confucianism of Oriental Enterprises" put forward the neo-Confucian life ideal of "self-cultivation, keeping the family in order, strengthening the enterprise and enriching the country" and the modern oriental enterprise culture of "benevolence, innovation, benefit, wisdom and trust", and was awarded to China. Chairman Xiu Laigui won the Innovation Award of Corporate Culture Management in China and the Founder Award of Corporate Philosophy in China.

Development goals

The development goal of revision pharmaceutical industry is to build a century-old revision and a national brand. By the end of 2006, the production line of raw material synthesis and preparation of gatifloxacin, a national first-class new drug with an investment of 654.38+0.2 billion yuan, has been built, and a first-class R&D base and the largest GAP Chinese herbal medicine production base in the province have been built with huge investment. Invest 1 100 million yuan to build 1000 GSP chain stores in Jilin Province.

Invest 10 billion yuan to build the most modern "Biomedical Science and Technology Park" in China. In 2004, it acquired Jilin Shuangyang Sika Deer Group and carried 340 million veteran industrial bases to adjust and transform special national debt projects, reorganized the former Beijing Xinluowei Pharmaceutical and the former Sichuan Kangxi Pharmaceutical, and planned to invest 250 million yuan to build the "Western Chinese Medicine Industrial Base of the Revised Pharmaceutical Group" in Dujiangyan City and 350 million yuan to build the largest Chinese medicine R&D base in Beijing. By 20 10, the sales revenue will reach 10 billion, and in 2030, it will become one of the top pharmaceutical enterprises in the world.